News
Pharnext raises € 7.7 million in a private placement
Pharnext raises € 7.7 million in a private placement
Pharnext Announces Encouraging Data from Open-Label Phase 3 Extension Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A (CMT1A)
Pharnext Announces Encouraging Data from Open-Label Phase 3 Extension Study of PXT3003 in Charcot-Marie-Tooth Disease Type 1A (CMT1A)
Pharnext establishes an equity line facility with Kepler Cheuvreux
Pharnext establishes an equity line facility with Kepler Cheuvreux
EUROPLASMA: Drawdown ot the second tranche of 200 convertible bonds
EUROPLASMA: Drawdown ot the second tranche of 200 convertible bonds
DGAP-News: Biom'up announces the approval of HEMOBLAST(TM) Bellows and its laparoscopic applicator in Australia
DGAP-News: Biom'up announces the approval of HEMOBLAST(TM) Bellows and its laparoscopic applicator in Australia
Valbiotis invited to present clinical results at the American Diabetes Association’s 84th Scientific Sessions
Valbiotis invited to present clinical results at the American Diabetes Association’s 84th Scientific Sessions
Valbiotis reaches an agreement to terminate its licensing and supply agreement with Nestlé Health Science
Valbiotis reaches an agreement to terminate its licensing and supply agreement with Nestlé Health Science
Valbiotis launches its e-commerce site for the marketing of Valbiotis®PRO Cholestérol
Valbiotis launches its e-commerce site for the marketing of Valbiotis®PRO Cholestérol
Valbiotis to launch its 100% natural dietary supplement for the management of hypercholesterolemia on the French market in May
Valbiotis to launch its 100% natural dietary supplement for the management of hypercholesterolemia on the French market in May
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections Four Years After One-Time Administration
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240319984906/en/
Graph 1: Evolution of Best-Corrected Visual Acuity
GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ® Gene Therapy at NANOS 2024
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240311531952/en/
Figure 1. Visual Recovery (CRR from Nadir) Among
GenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ® Gene Therapy at NANOS 2024
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240305810568/en/
(Graphic: Business Wire)
GenSight Biologics
Valbiotis presents its 2024 financial communication calendar
Valbiotis presents its 2024 financial communication calendar
Valbiotis sets out its commercial and clinical roadmap for 2024
Valbiotis sets out its commercial and clinical roadmap for 2024
Valbiotis announces the success of its €15 M capital increase
Valbiotis announces the success of its €15 M capital increase
Valbiotis announces the launch of a capital increase
Valbiotis announces the launch of a capital increase
Valbiotis announces the availability of an amendment to the Universal Registration Document
Valbiotis announces the availability of an amendment to the Universal Registration Document
Valbiotis announces that it has received Food and Drug Administration (FDA) approval for New Dietary Ingredient (NDI) status
Valbiotis announces that it has received Food and Drug Administration (FDA) approval for New Dietary Ingredient (NDI) status
Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes
Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes
Median Technologies Appoints Ben McDonald to its Board of Directors
Median Technologies (Paris:ALMDT) announced today that Ben McDonald has joined its Board of Directors, chaired by Oran Muduroglu. This appointment was approved during the ordinary shareholders’
VALBIOTIS SA: the Phase II/III REVERSE-IT study selected for an oral presentation at the 2023 EASD congress, the main European learned society for diabetes
VALBIOTIS SA: the Phase II/III REVERSE-IT study selected for an oral presentation at the 2023 EASD congress, the main European learned society for diabetes
Valbiotis publishes its financial report for the first half of 2023 and confirms its strategic roadmap
Valbiotis publishes its financial report for the first half of 2023 and confirms its strategic roadmap